$63.48—Stale · unknown old
NYSE • Last print unknown ago
$63.48—Stale · unknown old
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings completes $16.5 bln takeover of Catalent
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
Roche comes out against clearing takeover of drug manufacturer Catalent
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Catalent to sell New Jersey facility
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
Catalent delays filing of annual report